CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Amgen Inc.

AMGN
$219.86BMega Cap

Next catalyst

Phase 2November 2026

Anvumetostat

Advanced MTAP-null Solid Tumors

Get an email about AMGN's next catalysts

Track Amgen (AMGN) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 26 more upcoming events in our data (Phase 3 readout, Phase 2 readout).See the timeline

Catalyst Timeline

27 upcoming, 6 past

Phase 2Next

Anvumetostat Phase 2 Est. Readout

November 2026~Anvumetostat329

Estimated primary completion for Anvumetostat trial (NCT05094336) in Advanced MTAP-null Solid Tumors. Topline data typically follows completion by weeks to months.

Source
Phase 3

ABP 234 Phase 3 Est. Readout (Eucalyptus)

December 2026~ABP 234163

Primary completion for ABP 234 trial (NCT06430866) in Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)

Source
Phase 2

Blinatumomab Phase 2 Est. Readout

December 2026~Blinatumomab44

Estimated primary completion for Blinatumomab trial (NCT03114865) in Acute Lymphoblastic Leukemia. Topline data typically follows completion by weeks to months.

Source
Phase 2

AMG 732 Phase 2 Est. Readout

January 2027~AMG 73294

Primary completion for AMG 732 trial (NCT06401044) in Thyroid Eye Disease

Source
Phase 2

Pegfilgrastim Phase 2 Est. Readout

January 2027~pegfilgrastim90

Estimated primary completion for Pegfilgrastim trial (NCT03571633) in HER2-positive Breast Cancer. Topline data typically follows completion by weeks to months.

Source
Phase 3

Maridebart Cafraglutide Phase 3 Est. Readout (MARITIME-1)

January 2027~Maridebart cafraglutide3,853

Primary completion for Maridebart cafraglutide trial (NCT06858878) in Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight

Source
Phase 2

Autologous Stem Cell Transplant (ASCT) Phase 2 Est. Readout (ADVANCE)

February 2027~Autologous Stem Cell Transplant (ASCT)310

Estimated primary completion for Autologous Stem Cell Transplant (ASCT) trial (NCT04268498) in Multiple Myeloma. Topline data typically follows completion by weeks to months.

Source
Phase 2

Romosozumab Prefilled Syringe Phase 2 Est. Readout

March 2027~Romosozumab Prefilled Syringe30

Estimated primary completion for Romosozumab Prefilled Syringe trial (NCT04800367) in Premenopausal Idiopathic Osteoporosis. Topline data typically follows completion by weeks to months.

Source

How AMGN's past catalysts played out

Market Overview

Stock performance and key metrics

NASDAQBiological Products, (No Diagnostic Substances)Biotechnology🇺🇸North AmericaTHOUSAND OAKS31.5K employees

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.

Website
Drug Pipeline

Lumakras

Sotorasib

Approved

KRAS G12C NSCLC

Fast TrackBreakthroughPatent 2040

Cystagon®

Phase 3

Cystinosis

darbepoetin alfa

Phase 3

Anemia

Denosumab (AMG 162)

Phase 3

Postmenopausal Osteoporosis

mFOLFOX6

Phase 3

Gastric Cancer

Zoledronic Acid

Phase 3

Bone Metastases

Denosumab

Phase 3

Osteoporosis

ARM 2

Phase 3

Recurrent and/or Metastatic Head and Neck Cancer

Denosumab (CP2)

Phase 3

Postmenopausal Osteoporosis

Ustekinumab

Phase 3

Psoriasis

Topical treatments or phototherapy

Phase 3

Plaque Psoriasis

Standard Chemotherapy

Phase 3

Cancer

Oxaliplatin Based Chemotherapy

Phase 3

Colorectal Cancer

etanercept pre-filled syringe subcutaneous injection

Phase 3

Rheumatoid Arthritis

Chemotherapy

Phase 3

Gastric Cancer

Teprotumumab

Phase 3

Thyroid Eye Disease

1=Etanercept

Phase 3

Psoriasis

Tarlatamab

Phase 3

Small Cell Lung Cancer

OrphanFast TrackBreakthrough

Non-steroidal aromatase inhibitor therapy

Phase 3

Breast Cancer

Recombinant Human Keratinocyte Growth Factor

Phase 3

Stomatitis

Pegloticase

Phase 3

Uncontrolled Gout

Ibuprofen/famotidine

Phase 3

Ulcer

interferon γ-1b

Phase 3

Friedreich's Ataxia

Anakinra (Kineret®)

Phase 3

Rheumatoid Arthritis

Ocrelizumab (US)

Phase 3

Relapsing-remitting Multiple Sclerosis (RRMS)

Aranesp® (darbepoetin alfa)

Phase 3

Kidney Disease

Ibandronate

Phase 3

Postmenopausal Osteoporosis

ABP 710

Phase 3

Arthritis, Rheumatoid

Sotorasib

Phase 3

Non-small Cell Lung Cancer

AMG 386

Phase 3

Ovarian Cancer

AMG 510

Phase 3

KRAS p, G12c Mutated /Advanced Metastatic NSCLC

Statin therapy

Phase 3

Coronary Artery Disease (CAD)

Xaluritamig

Phase 3

Metastatic Castration-resistant Prostate Cancer

Darbepoetin alpha

Phase 3

Myelodysplastic Syndrome

filgrastim

Phase 3

Sarcoma

Erenumab Dose 1

Phase 3

Migraine

Etanercept/Autoinjector A

Phase 3

Rheumatoid Arthritis

Cytarabine

Phase 3

Lymphoma

TAC

Phase 3

Breast Cancer

Pegaspargase

Phase 3

Acute Lymphoblastic Leukemia

ABP 654

Phase 3

Plaque Psoriasis

Erenumab Dose 2

Phase 3

Migraine

Denosumab (for the open-label treatment phase)

Phase 3

Cancer

pegfilgrastim

Phase 3

Breast Cancer

Inebilizumab

Phase 3

IgG4 Related Disease

Dazodalibep

Phase 3

Sjögren's Syndrome (SS)

Topical agents

Phase 3

Psoriasis

AMG 162

Phase 3

Postmenopausal Osteoporosis

Cinacalcet HCl

Phase 3

Kidney Disease

ABP 234

Phase 3

Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

HPN-100

Phase 3

Cirrhosis

ABP 501

Phase 3

Arthritis, Rheumatoid

Low-intensity chemotherapy regimen

Phase 3

Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)

Palifermin

Phase 3

Head and Neck Cancer

romosozumab HCP administration with PFS

Phase 3

Post-Menopausal Osteoporosis

Olpasiran

Phase 3

Cardiovascular Disease

Cysteamine Bitartrate Delayed-release Capsules

Phase 3

Cystinosis

Romiplostim

Phase 3

Chemotherapy-induced Thrombocytopenia

Darbepoetin alfa and Epoetin alfa

Phase 3

Anemia

AMG 531

Phase 3

Thrombocytopenia

Omitted Vincristine+Dexamethasone pulses

Phase 3

Leukemia, Acute Lymphoblastic

AMG 162/Denosumab

Phase 3

Breast Cancer

Bemarituzumab

Phase 3

Gastric Cancer

Etanercept

Phase 3

Rheumatoid Arthritis

alendronate

Phase 3

Osteoporosis

Erenumab

Phase 3

Migraine

Maridebart cafraglutide

Phase 3

Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight

ABP 206

Phase 3

Melanoma

Irinotecan Based Chemotherapy

Phase 3

Colorectal Cancer

ABP 692

Phase 3

Relapsing-remitting Multiple Sclerosis (RRMS)

Alendronate Tab

Phase 3

Bone Density

Erenumab Dose 3

Phase 3

Migraine

Atorvastatin

Phase 3

Hyperlipidemia

Carfilzomib

Phase 3

Multiple Myeloma

Aeroquin

Phase 3

Cystic Fibrosis

Omnipaque

Phase 3

Cardiovascular Disease

Commercial Formulation Etanercept

Phase 3

Arthritis, Rheumatoid; Arthritis, Psoriatic

ABP 959

Phase 3

Paroxysmal Nocturnal Hemoglobinuria

Apremilast

Phase 3

Behçet's Disease

Etelcalcetide

Phase 3

Secondary Hyperparathyroidism

Bisphosphonate

Phase 3

Osteogenesis Imperfecta

Ezetimibe

Phase 3

Hyperlipidemia

Evolocumab Pre-filled Syringe

Phase 3

Primary Hypercholesterolemia

Panitumumab

Phase 3

Metastatic Colorectal Cancer

Romozosumab

Phase 3

Postmenopausal Osteoporosis

Metoprolol

Phase 3

Cardiovascular Disease

Cinacalcet

Phase 3

End Stage Renal Disease

Inotuzumab Ozogamicin+Standard Maintenance Therapy

Phase 3

Leukemia, Acute Lymphoblastic

Omitted Doxorubicin

Phase 3

Leukemia, Acute Lymphoblastic

Cystagon® (Cysteamine Bitartrate)

Phase 3

Cystinosis

Levitra (Vardenafil, BAY38-9456)

Phase 3

Erectile Dysfunction

New Formulation Etanercept

Phase 3

Arthritis, Rheumatoid; Arthritis, Psoriatic

Nitroglycerin

Phase 3

Cardiovascular Disease

Buphenyl (NaPBA)

Phase 3

Urea Cycle Disorders

Evolocumab

Phase 3

Hyperlipidemia

Rosuvastatin

Phase 3

Hyperlipidemia

Predniso(lo)ne

Phase 3

Primary Immune Thrombocytopenia

Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa

Phase 3

Breast Cancer

Evolocumab AI/pen

Phase 3

Primary Hypercholesterolemia

MR prednisone

Phase 3

Rheumatoid Arthritis

darbepoetin alfa SF

Phase 3

Kidney Disease

FOLFIRI Regimen

Phase 3

Metastatic Colorectal Cancer

HZT-501

Phase 3

Osteoarthritis

Epoetin alfa DT

Phase 3

Chronic Kidney Disease

Melphalan

Phase 3

Multiple Myeloma

6-tioguanine+Standard Maintenance Therapy

Phase 3

Leukemia, Acute Lymphoblastic

Romosozumab

Phase 3

Postmenopausal Women With Osteoporosis

Avacopan

Phase 3

Vasculitis

Sorafenib (Nexavar, BAY43-9006)

Phase 3

Thyroid Neoplasms

Lurbinectedin

Phase 3

Small Cell Lung Cancer (SCLC)

Cysteamine Bitartrate Delayed-release Capsules (RP103)

Phase 3

Cystinosis

Darbepoetin alpha (Aranesp)

Phase 3

Hematological Malignancies

ABP 798

Phase 3

Arthritis, Rheumatoid

ARM 1

Phase 3

Recurrent and/or Metastatic Head and Neck Cancer

Trifluridine and Tipiracil

Phase 3

Colorectal Cancer (CRC)

ABP 980

Phase 3

Breast Cancer

Rocatinlimab

Phase 3

Asthma

Denosumab (CP4)

Phase 3

Postmenopausal Osteoporosis

chemotherapy with LMWH - enoxaparin

Phase 3

Pancreatic Cancer

ABP 215

Phase 3

Non-small Cell Lung Cancer Metastatic

Talimogene laherparepvec

Phase 3

Melanoma

Apremilast (CC-10004)

Phase 3

Behcet Syndrome

Topical Therapy

Phase 3

Plaque Psoriasis

Vincrisitne

Phase 3

Leukemia, Acute Lymphoblastic

Lanadelumab

Phase 3

COVID-19

FOLFOX regimen

Phase 3

Metastatic Colorectal Cancer

RP103

Phase 3

Cystinosis

Blinatumomab

Phase 3

Acute Lymphoblastic Leukemia

AMG 073

Phase 3

Secondary Hyperparathyroidism

Aranesp®

Phase 3

Kidney Disease

rHuEPO

Phase 3

Cancer

Evolocumab AMD

Phase 3

Primary Hypercholesterolemia

Etanercept Liquid

Phase 3

Rheumatoid Arthritis

Romosozumab Prefilled Syringe

Phase 3

Bone Density, Low

MP-376 (Levofloxacin Solution for Inhalation)

Phase 3

Cystic Fibrosis

Risendronate

Phase 3

Steroid-induced Osteopor, Glucocorticoid-induced Ostepor

Epoetin alfa RB

Phase 3

Nephrology

Iron saccharate (Venofer)

Phase 3

Hematological Malignancies

Actonel®

Phase 3

Osteoporosis

De Novo Administration of Darbepoetin Alfa

Phase 3

Chronic Kidney Disease

Background Statin Therapy

Phase 3

Dyslipidemia

ABP 938

Phase 3

Neovascular (Wet) Age-related Macular Degeneration (AMD)

Ivabradine

Phase 3

Postural Orthostatic Tachycardia Syndrome

Oral methotrexate

Phase 3

Rheumatoid Arthritis

Dexamthasone

Phase 3

Acute Lymphoblastic Leukemia

Tezepelumab (AI)

Phase 3

Asthma

Ganitumab

Phase 2

Advanced Solid Tumors

pegsunercept

Phase 2

Rheumatoid Arthritis

tacrolimus (standard GVHD prophylaxis)

Phase 2

Graft Versus Host Disease

R-CHOEP14x6+HD-AraC+HD-Mtx

Phase 2

Diffuse Large B-Cell Lymphoma

Panitumumab + paclitaxel

Phase 2

Head and Neck Cancer

Panitumumab and CPT-11

Phase 2

Metastatic Colorectal Cancer

AGM 719

Phase 2

Rheumatoid Arthritis

MEDI9929

Phase 2

Atopic Dermatitis

Amgen 386

Phase 2

Glioblastoma Multiforme

Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta

Phase 2

Unresectable Locally Advanced NSCLC

Inotuzumab

Phase 2

Acute Lymphoblastic Leukemia

Subcutaneous Blinatumomab

Phase 2

CD19 Positive

Talimogene Laherparepvec (T-VEC)

Phase 2

Sarcoma

Carfilzomib & Non-IMiD Regimen

Phase 2

Multiple Myeloma

Panitumumab + FOLFOX (no-DP)

Phase 2

Metastatic Colorectal Cancer

Bleomycin sulfate

Phase 2

Sarcoma, Kaposi

Oral Contraceptive Pills (OCPs)

Phase 2

Amenorrhea

Erenumab-aooe (EREN) s.c. administered every four weeks for a total of five treatments

Phase 2

Temporomandibular Disorder

Vinblastine sulfate

Phase 2

HIV Infections

PEG asparaginase

Phase 2

Lymphoblastic Leukemia

bemarituzumab, trifluridine/tipiracil

Phase 2

Metastatic Gastro-esophageal Adenocarcinoma

AMG 102 and erlotinib

Phase 2

Carcinoma, Non-Small-Cell Lung

Anvumetostat

Phase 2

Advanced MTAP-null Solid Tumors

bemarituzumab, irinotecan

Phase 2

Metastatic Gastro-esophageal Adenocarcinoma

Panitumumab + FOLFOX (DP)

Phase 2

Metastatic Colorectal Cancer

Carfilzomib + Ibrutinib

Phase 2

Waldenstrom Macroglobulinemia

CC10004

Phase 2

Psoriasis

Filgrastim-SD/01

Phase 2

Non-small Cell Lung Cancer

Mitozantrone

Phase 2

Non-Hodgkin's Lymphoma

Alendronate Effervescent Oral Tablet

Phase 2

Erosive Osteoarthritis

Pegfilgrastim (Neulasta)

Phase 2

Multiple Myeloma

Intervention A: Irinotecan; Oxaliplatin; Neulasta

Phase 2

Non-Small Cell Lung Cancer

Adecatumumab

Phase 2

Liver Metastases

AMG 531 (Romiplostim)

Phase 2

MDS

IV Bisphosphonates

Phase 2

Breast Cancer

AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P)

Phase 2

Breast Cancer

panitumumab, mytomicin C, 5-FU, radiation

Phase 2

Anal Squamous Cell Carcinoma

docetaxel + cyclophosphamide + pegfilgrastim

Phase 2

Female Breast Cancer

Rituximab + ACVBP regimen plus Pegfilgrastim

Phase 2

Untreated CD20-positive Large B-cell Lymphoma

Darbepoetin alfa SC

Phase 2

Anemia

T-VEC

Phase 2

Melanoma Stage III

5-Fluorouracil

Phase 2

Colorectal Cancer

Panitumumab (ABX-EGF)

Phase 2

Advanced Renal Cell Carcinoma

AMG 853

Phase 2

Asthma

epratuzumab

Phase 2

Non-Hodgkin's Lymphoma

cinacalcet (AMG 073)

Phase 2

Secondary Hyperparathyroidism

Antizol

Phase 2

Aldehyde Dehydrogenase-2 (ALDH2) Deficiency

N-Plate/romiplostim

Phase 2

Myelodysplastic Syndromes

VIB7734

Phase 2

Lupus Erythematosus, Systemic

Modified FOLFOX6

Phase 2

Advanced Solid Tumors

AMG 827

Phase 2

Asthma

IV Bisphosphonate q 4 weeks

Phase 2

Bone Metastases in Men With Hormone-Refractory Prostate Cancer

Pegsunercept (PEG sTNF-RI)

Phase 2

Rheumatoid Arthritis

MP-376

Phase 2

Cystic Fibrosis (CF)

Teriparatide

Phase 2

Low Bone Mineral Density

CCX354-C

Phase 2

Rheumatoid Arthritis

CCX140-B

Phase 2

Diabetic Nephropathy

Autologous Stem Cell Transplant (ASCT)

Phase 2

Multiple Myeloma

AMG 655

Phase 2

Metastatic Colorectal Cancer

BUPHENYL®

Phase 2

Urea Cycle Disorders

CCX-354-C

Phase 2

Rheumatoid Arthritis

Tarlatamab treatment

Phase 2

DLL3-expressing Tumors

Carfilzomib for Inj 60 milligram (MG)

Phase 2

Multiple Myeloma in Relapse

Pre-emptive Skin Treatment

Phase 2

Metastatic Colorectal Cancer

AMG 479

Phase 2

Neuroendocrine Tumor

MTX/ARA-C

Phase 2

B-cell Acute Lymphoblastic Leukemia

ABX-EGF

Phase 2

Non-small Cell Lung Cancer

VIB4920

Phase 2

Sjögren's Syndrome

Belatacept

Phase 2

Allografts

Conatumumab

Phase 2

Colon Cancer

AMG 714

Phase 2

Psoriasis

AMG 719

Phase 2

Rheumatoid Arthritis

AMG 732

Phase 2

Thyroid Eye Disease

Abrilumab

Phase 2

Ulcerative Colitis

Brodalumab

Phase 2

Rheumatoid Arthritis

Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)

Phase 2

Anemia

Tezepelumab Dose 1

Phase 2

Chronic Spontaneous Urticaria

Cysteamine Bitartrate

Phase 2

Inherited Mitochondrial Disease, Including Leigh Syndrome

Recombinant Human Erythropoietin

Phase 2

Breast Cancer

CCX168

Phase 2

Vasculitis

ABX-EGF (panitumumab)

Phase 2

Metastatic Colorectal Cancer

IDE397

Phase 2

MTAP-null Non-Small-Cell Lung Cancer

recombinant human erythropoietin (rHuEPO)

Phase 2

Gynecological Malignancies

AMG 951 (rhApo2L/TRAIL)

Phase 2

Non-Small Cell Lung Cancer

HZN-1116

Phase 2

Sjogren's Syndrome

AMG 193

Phase 2

MTAP-deleted NSCLC

Systemic AMG 108

Phase 2

Osteoarthritis

Blinatumomab (MT103)

Phase 2

Acute Lymphoblastic Leukemia

anakinra

Phase 2

Rheumatoid Arthritis

AMG 317

Phase 2

Asthma

Liatermin

Phase 2

Parkinson's Disease

Daxdilimab

Phase 2

Alopecia Areata

AMG 151

Phase 2

Diabetes Mellitus

Intra-articular metHuIL-1ra (anakinra)

Phase 2

Osteoarthritis

IV iron dextran

Phase 2

Anemia

Neulasta

Phase 2

Breast Cancer

CC-11050

Phase 2

Cutaneous Lupus Erythematosus

Erenumab PFS

Phase 2

Migraine

CCX 354-C

Phase 2

Rheumatoid Arthritis

AMG 706

Phase 2

Gastrointestinal Cancer

AMG 337

Phase 2

Stomach Neoplasms

6-Mercaptopurine

Phase 2

Acute Lymphoblastic Leukemia

Naproxen

Phase 2

Bone Pain in Stage I - III Breast Cancer

CC-10004

Phase 2

Psoriasis

Oprozomib

Phase 2

Multiple Myeloma

Previous denosumab

Phase 2

Low Bone Mass

Sensipar (Cinacalcet HCl)

Phase 2

Secondary Hyperparathyroidism

Calaspargase

Phase 2

Acute Lymphoblastic Leukemia

AMG 301

Phase 2

Chronic Migraine or Episodic Migraine

AMG 108

Phase 2

Rheumatoid Arthritis

Lodotra

Phase 2

Asthma

CCX282-B

Phase 2

Crohn's Disease

AMG 223

Phase 2

End Stage Renal Disease

Reactive Skin Treatment

Phase 2

Metastatic Colorectal Cancer

NaPBA

Phase 2

Urea Cycle Disorders

Motesanib diphosphate

Phase 2

Lung Cancer

AMG 102

Phase 2

Cancer

RCHOP

Phase 2

Richter Syndrome

Romidepsin

Phase 2

Peripheral T Cell Lymphoma

Epirubicin, Cisplatin, Capecitabine, Panitumumab

Phase 2

Stomach Neoplasms

RAD

Phase 2

Multiple Myeloma

Interferon gamma-1b

Phase 2

Acute Myeloid Leukemia

AMG 334

Phase 2

Post-Traumatic Headache

CPT-11

Phase 2

Non Small Cell Lung Cancer

Denosumab Prefilled Syringe

Phase 2

Premenopausal Idiopathic Osteoporosis

liposomal cytarabine

Phase 2

Primary Disease

5FU

Phase 2

Squamous Cell Carcinoma of Head and Neck

CEEP regimen

Phase 2

Lymphoma

Mini-CVD

Phase 2

B-cell Acute Lymphoblastic Leukemia

standard chemotherapy (7+3 scheme): Daunorubicin, Cytarabine

Phase 2

Acute Myeloid Leukemia

Consolidation with 4 cycles of CarCyDex

Phase 2

Multiple Myeloma

TALIMOGENE LAHERPAREPVEC (TVEC)

Phase 2

Melanoma

Adecatumumab and FOLFOX

Phase 2

Liver Metastases

Intervention B: Etoposide; Carboplatin; Neulasta

Phase 2

Non-Small Cell Lung Cancer

Donor Leukocyte Infusion (DLI)

Phase 2

Acute Myeloid Leukemia

Erenumab AI/Pen

Phase 2

Migraine

Myocet

Phase 2

Breast Cancer

Aranesp

Phase 2

Prostate Cancer

FOLFOXIRI + Panitumumab

Phase 2

Metastatic Colorectal Cancer

Panitumumab+irinotecan

Phase 2

Metastatic Colorectal Cancer

Denosumab/Subcutaneous

Phase 2

Multiple Myeloma

Maintenance Chemotherapy

Phase 2

Metastatic Colorectal Cancer

5Fluorouracil

Phase 2

Rectal Cancer

epirubicin hydrochloride

Phase 2

Breast Cancer

Randomization to No Panitumumab

Phase 2

Metastatic Colorectal Cancer

Trebananib

Phase 2

Advanced Renal Cell Carcinoma

Doxycycline

Phase 2

Skin Toxicity

TVEC into target lesions - week 1-2

Phase 2

Squamous Cell Carcinoma

leucovorin calcium

Phase 2

Mucinous Adenocarcinoma of the Colon

r-metHuLeptin

Phase 2

HAART-induced Lipodystrophy and Metabolic Syndrome

AMG 557/MEDI5872

Phase 2

Primary Sjögren's Syndrome

Doxorubicin hydrochloride (liposomal)

Phase 2

Sarcoma, Kaposi

Dapagliflozin Tab

Phase 2

HFrEF

Acyclovir

Phase 2

Metastatic Castration-resistant Prostate Cancer

Denosumab Q4W

Phase 2

Multiple Myeloma

bemarituzumab, paclitaxel, ramucirumab

Phase 2

Metastatic Gastro-esophageal Adenocarcinoma

TVEC into target lesions 3wks after 1st injection

Phase 2

Squamous Cell Carcinoma

TVEC into target lesions 2wks after 2nd injection

Phase 2

Squamous Cell Carcinoma

KRdD followed by auto-HCT

Phase 2

Multiple Myeloma

TVEC into target lesions 2wks after 3rd injection

Phase 2

Squamous Cell Carcinoma

Carfilzomib & IMiD containing regimen

Phase 2

Multiple Myeloma

KRdD only

Phase 2

Multiple Myeloma

Rozibafusp Alfa

Phase 2

Systemic Lupus Erythematosus (SLE)

Diphenhydramine

Phase 2

Multiple Myeloma

AMG 509

Phase 1

Prostate Cancer

Fast Track

eosinophilic esophagitis

3 drugs in this indication

Temporomandibular Disorder

2 drugs in this indication

KRAS G12C NSCLC

1 drug in this indication

Small Cell Lung Cancer

1 drug in this indication

Prostate Cancer

1 drug in this indication

reduction of cardiovascular risk, prevention of first myocardial infarction or stroke

1 drug in this indication

Cardiovascular risk reduction, primary prevention of myocardial infarction and stroke

1 drug in this indication

eosinophilic esophagitis (EoE), asthma, chronic rhinosinusitis with nasal polyps (CRSwNP)

1 drug in this indication

Reduction of risk of first myocardial infarction or stroke in patients with cardiovascular disease

1 drug in this indication

Systemic Lupus Erythematosus (SLE)

1 drug in this indication

primary prevention of myocardial infarction and stroke

1 drug in this indication

rare disease

1 drug in this indication

Reduction of risk of first myocardial infarction or stroke

1 drug in this indication

reduction of risk of first heart attack or stroke

1 drug in this indication

Obesity

1 drug in this indication

lung cancer

1 drug in this indication

Rheumatoid Arthritis

1 drug in this indication

oncology

1 drug in this indication

rare kidney disease

1 drug in this indication

ANCA-associated vasculitis (AAV)

1 drug in this indication

Asthma with swallowing disorder

1 drug in this indication

Extensive-stage small cell lung cancer (frontline maintenance)

1 drug in this indication

first-line maintenance treatment of small cell lung cancer

1 drug in this indication

First-line extensive stage small cell lung cancer (ES-SCLC)

1 drug in this indication

Extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy

1 drug in this indication

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

Frequently asked questions

What is in Amgen Inc.'s drug pipeline?→

CatalystAlert tracks 311 drug candidates in Amgen Inc.'s (AMGN) pipeline across Phase 3, Phase 2, Phase 1, Approved. Its lead program is Lumakras (Approved). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Amgen Inc.'s next FDA catalyst?→

Amgen Inc.'s (AMGN) next tracked catalyst is a Phase 2 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track AMGN biotech catalysts?→

Add AMGN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Amgen Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply